WIN 55,212-2
From Wikipedia, the free encyclopedia
WIN 55,212-2 | |
---|---|
Chemical name | (R)-(+)-[2,3-Dihydro-5-methyl- 3-(4-morpholinylmethyl)pyrrolo [1,2,3-de)-1,4-benzoxazin-6-yl]- 1-napthalenylmethanone |
Chemical formula | C27H26N2O3 |
Molecular mass | 522.61 g/mol |
WIN 55,212-2 is a chemical agent in the Cannabinoid family.
WIN 55,212-2 is a potent cannabinoid receptor agonist1, potent analgesic2 in a rat model of neuropathic pain3. It activates p42 and p44 MAP kinase via receptor-mediated signaling4.
WIN55,212-2, along side HU-210 and JWH-133, are implicated in preventing the inflamation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This antiinflmatory action is induced through the agonization of cannabinoid receptors which prevents microglial activation that elicits the inflamation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models.
[edit] External links
- Biomol Win 55,212-2 Data Sheet
- The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. 2006 Jul 18; More information in PubMed for 16849427
- JNeurosci.orgPrevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
- New Scientist: Hope for cannabis-based drug for Alzheimer's
[edit] References
- C.C. Felder et al. Mol. Pharmacol. 1995 48 443
- I.D. Meng et al. Nature 1998 395 381
- U. Herzberg et al. Neurosci. Lett. 1997 221 157
- M. Bouaboula et al. Biochem. J. 1995 312 637